The Week in Review: February 2 – February 9, 2018

Friday, February 9, 2018 News Recap: Epidemiology: CTAC Launches Campaign to End Hepatitis C in Canada. The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action. #EASLmono: Expanding the conversation on hepatitis elimination. The recent European...

Attention Hepatitis B (HBV) Patients & Caregivers – Your Help Requested

Do you have HEPATITIS B or are you a CAREGIVER for someone with HBV? This is really important for you! An improved hepatitis B treatment will likely be covered by BC (Canada) PharmaCare soon, but first the BC government has requested HepCBC to submit a patient group review explaining whether hepatitis B patients want this new treatment, and why. SURVEY – ANSWER 5 QUESTIONS BELOW BY EMAIL or PHONE (English or Chinese 中文 ) HepCBC needs to hear your voice

The Week in Review: September 22 – September 29, 2017

Friday, September 29, 2017 News Recap: Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...

Hepatitis B (HBV) Patients & Caregivers – Your Help Requested re Vemlidy

Do you have HEPATITIS B or are you a CAREGIVER for someone with HBV? This is really important for you! An improved hepatitis B treatment will likely be available to Canadians soon, but first the federal government has requested us to submit a patient group review to them (CADTH) explaining whether hepatitis B patients want this new treatment, and why. What is the new hepatitis B treatment? It is tenofovir alafenamide or TAF (brand name VemlidyTM) made by

Gilead Receives Approval in Canada for VEMLIDY™ (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

MISSISSAUGA, ON, June 19, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for VEMLIDY™ (tenofovir alafenamide, TAF) 25mg tablets, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease. – VEMLIDY is a Once-Daily Treatment that Demonstrated Similar Efficacy with Improved Renal and Bone Laboratory Safety Parameters C

USA: FDA Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

Vemlidy is a Once-Daily Treatment that Demonstrated Similar Efficacy with Improved Renal and Bone Laboratory Safety Parameters Compared to Viread FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy® (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated li